Combination Therapy of Ursodeoxycholic Acid and Corticosteroids for Primary Biliary Cirrhosis with Features of Autoimmune Hepatitis: A Meta-Analysis

被引：19

作者：

Zhang, Yan ^{[1
]}

Lu, Jie ^{[1
]}

Dai, Weiqi ^{[1
]}

Wang, Fan ^{[1
]}

Shen, Miao ^{[1
]}

Yang, Jing ^{[1
]}

Zhu, Rong ^{[1
]}

Zhang, Huawei ^{[1
]}

Chen, Kan ^{[1
]}

Cheng, Ping ^{[1
]}

He, Lei ^{[1
]}

Wang, Chengfen ^{[1
]}

Xu, Ling ^{[1
]}

Zhou, Yingqun ^{[1
]}

Guo, Chuanyong ^{[1
]}

机构：

[1] Tongji Univ, Sch Med, Dept Gastroenterol, Shanghai Peoples Hosp 10, Shanghai 200072, Peoples R China

来源：

GASTROENTEROLOGY RESEARCH AND PRACTICE | 2013年 / 2013卷

基金：

中国国家自然科学基金;

关键词：

OVERLAP SYNDROME; QUALITY; BUDESONIDE; TRIALS;

D O I：

10.1155/2013/490731

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

A meta-analysis was performed of RCTs comparing therapies that combine UDCA and corticosteroids with UDCA monotherapy. In this paper, we found that the combination therapy of UDCA and corticosteroids was more effective for PBC-AIH.

引用

页数：9

共 50 条

[1] Combination therapy of bezafibrate and ursodeoxycholic acid for primary biliary cirrhosis: A meta-analysis
Zhang, Yan
Chen, Kan
Dai, Weiqi
Xia, Yujing
Wang, Fan
Shen, Miao
Cheng, Ping
Wang, Chengfen
Yang, Jing
Zhu, Rong
Zhang, Huawei
Li, Jingjing
Zheng, Yuanyuan
Wang, Junshan
Lu, Jie
Zhou, Yingqun
Guo, Chuanyong
HEPATOLOGY RESEARCH, 2015, 45 (01) : 48 - 58
[2] Ursodeoxycholic acid and primary biliary cirrhosis with features of autoimmune hepatitis
Chazouillères, O
Poupon, R
HEPATOLOGY, 2002, 36 (04) : 1026 - 1027
[3] Primary biliary cirrhosis with additional features of autoimmune hepatitis: Response to therapy with ursodeoxycholic acid
Joshi, S
Cauch-Dudek, K
Wanless, IR
Lindor, KD
Jorgensen, R
Batts, K
Heathcote, EJ
HEPATOLOGY, 2002, 35 (02) : 409 - 413
[4] Ursodeoxycholic acid and primary biliary cirrhosis with features of autoimmune hepatitis - Reply
Joshi, S
Heathcote, EJ
HEPATOLOGY, 2002, 36 (04) : 1027 - 1027
[5] Response to ursodeoxycholic acid in primary biliary cirrhosis patients with additional features of autoimmune hepatitis.
Joshi, S
Cauch-Dudek, K
Wanless, IR
Heathcote, EJ
HEPATOLOGY, 1999, 30 (04) : 496A - 496A
[6] Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis
Goulis, J
Leandro, G
Burroughs, AK
LANCET, 1999, 354 (9184): : 1053 - 1060
[7] Combination therapy of ursodeoxycholic acid and glucocorticoid and (or) immunosuppressant in patients with primary biliary cholangitis A meta-analysis
Wang, Zi-Long
Song, Kai-Min
Jin, Rui
Xie, Yan-Di
Wang, Yu-Qiong
Liu, Zhi-Cheng
Feng, Bo
MEDICINE, 2022, 101 (09) : E28987
[8] Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis
Zhang, Yan
Li, Sainan
He, Lei
Wang, Fan
Chen, Kan
Li, Jingjing
Liu, Tong
Zheng, Yuanyuan
Wang, Jianrong
Lu, Wenxia
Zhou, Yuqing
Yin, Qin
Xia, Yujing
Zhou, Yingqun
Lu, Jie
Guo, Chuanyong
DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 2757 - 2766
[9] Ursodeoxycholic acid in combination with prednisolone or budenoside in the therapy of primary biliary cirrhosis
Leuschner, U
Maier, KP
Guldutuna, S
Parte-Peterhans, S
Leuschner, M
BILE ACIDS IN HEPATOBILIARY DISEASES: BASIC RESEARCH AND CLINICAL APPLICATION, 1997, 93 : 299 - 302
[10] Combination therapy with mycophenolate mofetil and ursodeoxycholic acid for primary biliary cirrhosis
Jones, EA
ten Kate, FJW
ter Borg, F
Houben, M
Reesink, HW
Chamuleau, RAFM
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1999, 11 (10) : 1165 - 1169

← 1 2 3 4 5 →